TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Attention Deficit Disorder With Hyperactivity

In brief

The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.

Key facts

Study ID

NCT02083783

Run by

Tris Pharma, Inc.

People needed

108

Starts

2014-03-01

Expected to finish

2014-12-01

Last updated by the study team

2020-08-26

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition

You may not qualify if…

• Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD

Where it is running

• Newport Beach Clinical Research Associates, Inc. — Newport Beach, California, United States
• Center for Psychiatry and Behavioral Medicine, Inc. — Las Vegas, Nevada, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Bayou City Research — Houston, Texas, United States
• Westex Clinical Investigation — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.